Market closed
Chimerix/$CMRX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Chimerix
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
Ticker
$CMRX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
72
Website
Chimerix Metrics
BasicAdvanced
$311M
Market cap
-
P/E ratio
-$0.94
EPS
1.13
Beta
-
Dividend rate
Price and volume
Market cap
$311M
Beta
1.13
52-week high
$3.61
52-week low
$0.75
Average daily volume
7.9M
Financial strength
Current ratio
6.334
Quick ratio
6.131
Long term debt to equity
0.474
Total debt to equity
0.474
Management effectiveness
Return on assets (TTM)
-30.22%
Return on equity (TTM)
-48.59%
Valuation
Price to revenue (TTM)
1,946.007
Price to book
2.29
Price to tangible book (TTM)
2.29
Price to free cash flow (TTM)
-4.391
Growth
Revenue change (TTM)
-85.98%
Earnings per share change (TTM)
-2.37%
3-year revenue growth (CAGR)
-62.66%
3-year earnings per share growth (CAGR)
-20.19%
What the Analysts think about Chimerix
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Chimerix stock.
Chimerix Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Chimerix Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Chimerix News
AllArticlesVideos
Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma
GlobeNewsWire·17 hours ago
Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy
Seeking Alpha·3 weeks ago
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Chimerix stock?
Chimerix (CMRX) has a market cap of $311M as of December 31, 2024.
What is the P/E ratio for Chimerix stock?
The price to earnings (P/E) ratio for Chimerix (CMRX) stock is 0 as of December 31, 2024.
Does Chimerix stock pay dividends?
No, Chimerix (CMRX) stock does not pay dividends to its shareholders as of December 31, 2024.
When is the next Chimerix dividend payment date?
Chimerix (CMRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Chimerix?
Chimerix (CMRX) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.